Eli Lilly rises premarket as new lung cancer data raises hopes
FROM THE WIRE · GURUFOCUS.COM
Eli Lilly (LLY) shares climbed nearly 1% in pre-market trading after clinical data showed its experimental drug olomorasib shrank tumors in 62% of patients when
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive trial data on an experimental drug can support the stock of a large pharma company.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Eli Lilly shares climbed nearly 1% in pre-market trading.
- 02The experimental drug olomorasib shrank tumors in 62% of patients.
- 03The data concerns lung cancer.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets